within Pharmacolibrary.Drugs.ATC.L;

model L01XX73
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.37,
    Cl             = 0.43666666666666665,
    adminDuration  = 600,
    adminMass      = 0.96,
    adminCount     = 1,
    Vd             = 0.211,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.004166666666666667,
    Tlag           = 9.6
  );

  annotation(Documentation(
    info ="<html><body><p>Sotorasib is an orally administered, small-molecule irreversible inhibitor of KRAS G12C, used for the treatment of non-small cell lung cancer (NSCLC) in patients with KRAS G12C mutation. It was approved by the FDA in 2021 and is actively in use for its labeled indication.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters as reported in adult patients with advanced solid tumors, primarily non-small cell lung cancer, after oral administration.</p><h4>References</h4><ol><li><p>Vuu, I, et al., &amp; Houk, BE (2023). Impact of Sotorasib on the Pharmacokinetics and Pharmacodynamics of Metformin, a MATE1/2K Substrate, in Healthy Subjects. <i>Clinical pharmacokinetics</i> 62(2) 267–275. DOI:<a href=&quot;https://doi.org/10.1007/s40262-022-01192-5&quot;>10.1007/s40262-022-01192-5</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36529835/&quot;>https://pubmed.ncbi.nlm.nih.gov/36529835</a></p></li><li><p>Cardona, P, et al., &amp; Houk, B (2024). Effect of Strong CYP3A4 Inhibition, CYP3A4 Induction, and OATP1B1/3 Inhibition on the Pharmacokinetics of a Single Oral Dose of Sotorasib. <i>Clinical pharmacology in drug development</i> 13(7) 810–818. DOI:<a href=&quot;https://doi.org/10.1002/cpdd.1392&quot;>10.1002/cpdd.1392</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38421129/&quot;>https://pubmed.ncbi.nlm.nih.gov/38421129</a></p></li><li><p>Cardona, P, et al., &amp; Houk, B (2024). Impact of a High-Fat Meal on the Pharmacokinetics of Sotorasib, a KRAS G12C Inhibitor. <i>Clinical pharmacology in drug development</i> 13(11) 1219–1226. DOI:<a href=&quot;https://doi.org/10.1002/cpdd.1452&quot;>10.1002/cpdd.1452</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/39016337/&quot;>https://pubmed.ncbi.nlm.nih.gov/39016337</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L01XX73;
